Literature DB >> 17934067

The role of Ikaros in human erythroid differentiation.

Marilyne Dijon1, Florence Bardin, Anne Murati, Michèle Batoz, Christian Chabannon, Cécile Tonnelle.   

Abstract

Ikaros--a factor that positively or negatively controls gene transcription--is active in murine adult erythroid cells, and involved in fetal to adult globin switching. Mice with Ikaros mutations have defects in erythropoiesis and anemia. In this paper, we have studied the role of Ikaros in human erythroid development for the first time. Using a gene-transfer strategy, we expressed Ikaros 6 (Ik6)--a known dominant--negative protein that interferes with normal Ikaros activity-in cord blood or apheresis CD34(+) cells that were induced to differentiate along the erythroid pathway. Lentivirally induced Ik6-forced expression resulted in increased cell death, decreased cell proliferation, and decreased expression of erythroid-specific genes, including GATA1 and fetal and adult globins. In contrast, we observed the maintenance of a residual myeloid population that can be detected in this culture system, with a relative increase of myeloid gene expression, including PU1. In secondary cultures, expression of Ik6 favored reversion of sorted and phenotypically defined erythroid cells into myeloid cells, and prevented reversion of myeloid cells into erythroid cells. We conclude that Ikaros is involved in human adult or fetal erythroid differentiation as well as in the commitment between erythroid and myeloid cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934067     DOI: 10.1182/blood-2007-07-098202

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Ikaros limits basophil development by suppressing C/EBP-α expression.

Authors:  Kavitha N Rao; Craig Smuda; Gregory D Gregory; Booki Min; Melissa A Brown
Journal:  Blood       Date:  2013-08-29       Impact factor: 22.113

2.  Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia.

Authors:  Jasmijn D E de Rooij; Eva Beuling; Marry M van den Heuvel-Eibrink; Askar Obulkasim; André Baruchel; Jan Trka; Dirk Reinhardt; Edwin Sonneveld; Brenda E S Gibson; Rob Pieters; Martin Zimmermann; C Michel Zwaan; Maarten Fornerod
Journal:  Haematologica       Date:  2015-06-11       Impact factor: 9.941

3.  Normal hematologic parameters and fetal hemoglobin silencing with heterozygous IKZF1 mutations.

Authors:  Nour Abdulhay; Claudia Fiorini; Attila Kumánovics; Ashleigh A Sun; Jeannette Hansen-Rejali; Karl V Voelkerding; Sergio D Rosenzweig; Harry R Hill; Vijay G Sankaran
Journal:  Blood       Date:  2016-08-31       Impact factor: 22.113

4.  Ikaros represses and activates PU.1 cell-type-specifically through the multifunctional Sfpi1 URE and a myeloid specific enhancer.

Authors:  M A Zarnegar; E V Rothenberg
Journal:  Oncogene       Date:  2012-01-09       Impact factor: 9.867

5.  Congenital pancytopenia and absence of B lymphocytes in a neonate with a mutation in the Ikaros gene.

Authors:  Frederick D Goldman; Zafer Gurel; Duha Al-Zubeidi; Ari J Fried; Michael Icardi; Chunhua Song; Sinisa Dovat
Journal:  Pediatr Blood Cancer       Date:  2011-05-05       Impact factor: 3.167

6.  Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling.

Authors:  Sébastien Malinge; Clarisse Thiollier; Timothy M Chlon; Louis C Doré; Lauren Diebold; Olivier Bluteau; Vinciane Mabialah; William Vainchenker; Philippe Dessen; Susan Winandy; Thomas Mercher; John D Crispino
Journal:  Blood       Date:  2013-01-18       Impact factor: 22.113

7.  Ikaros: master of hematopoiesis, agent of leukemia.

Authors:  Kara L Davis
Journal:  Ther Adv Hematol       Date:  2011-12

8.  Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors.

Authors:  Brian M Dulmovits; Abena O Appiah-Kubi; Julien Papoin; John Hale; Mingzhu He; Yousef Al-Abed; Sebastien Didier; Michael Gould; Sehba Husain-Krautter; Sharon A Singh; Kyle W H Chan; Adrianna Vlachos; Steven L Allen; Naomi Taylor; Philippe Marambaud; Xiuli An; Patrick G Gallagher; Narla Mohandas; Jeffrey M Lipton; Johnson M Liu; Lionel Blanc
Journal:  Blood       Date:  2015-12-17       Impact factor: 22.113

Review 9.  IKAROS-Associated Diseases in 2020: Genotypes, Phenotypes, and Outcomes in Primary Immune Deficiency/Inborn Errors of Immunity.

Authors:  Hye Sun Kuehn; Cristiane J Nunes-Santos; Sergio D Rosenzweig
Journal:  J Clin Immunol       Date:  2021-01-03       Impact factor: 8.317

Review 10.  Germline IKZF1 mutations and their impact on immunity: IKAROS-associated diseases and pathophysiology.

Authors:  Hye Sun Kuehn; Cristiane J Nunes-Santos; Sergio D Rosenzweig
Journal:  Expert Rev Clin Immunol       Date:  2021-03-19       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.